Big $ R&D Spenders
January 13, 2009 | Terry Sharrer
Genetic Engineering & Biotechnology News reported recently that GSK’s deal with Actelion, worth almost $3.2 billion, for Actelion’s insomnia drug in Phase III trials was the most valuable collaboration in R&D collaborations last year. Following that, Celgene and Acceleron Pharma’s agreement on an early-stage bone loss drug, and Takeda and Amgen’s collaboration on a chemotherapeutic for non-small-cell lung cancer had the highest spending. MORE